CHRS Should I Buy

CHRS is not a good buy right now for a Beginner long-term investor with $50k–$100k who is impatient. While sentiment has improved (recent bullish initiation/upgrade and very call-heavy options positioning), the stock is still a highly event-driven oncology name with large losses and extreme implied volatility. With today’s sharp drop (~-9%) and price sitting just below near-term resistance, the risk/reward is not attractive enough to recommend an immediate long-term entry.

Trend & momentum: The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an uptrend structure. MACD histogram is positive (0.0856) but “positively contracting,” which often signals fading upside momentum after a run-up. RSI(6) at ~69.3 is near overbought, consistent with a stock that recently ran and is now pulling back. Price levels: Pivot support is ~2.001 (key near-term line to hold). Immediate resistance is R1 ~2.424, then R2 ~2.684. With the current price at 2.29 after a -8.96% down day, CHRS is in a pullback within an uptrend, but it’s still below the first resistance band (2.42–2.68). Pattern-based short-term outlook (provided): ~70% chance of -0.34% next day, +2.76% next week, +8.36% next month—mildly bullish beyond the very near term, but not a strong “must-buy-now” setup. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.